NCT06399341

Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).

Name: Clinical Trial NCT06399341
Creator: Elpen Pharmaceutical Co. Inc.
Keywords: Papillomavirus Infections, Papilocare vaginal gel, device, clinical trial, Greece

PAPILOBS GR: A Clinical Investigation to Assess the Effectiveness of PAPILOCARE® in the Regression of Cervix Cytological Abnormalities Caused by HPV.

Elpen Pharmaceutical Co. Inc.·ClinicalTrials.gov·device·Device trialCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Papillomavirus Infections
Drug/Device/Intervention: Papilocare vaginal gel
Study type: Observational
Intervention type: device

Sponsor & location

Primary sponsor: Elpen Pharmaceutical Co. Inc.
Location: Ioannina,Larissa,Patra,Thessaloniki, Greece

Timeline & enrollment

Phase: N/A
Start date: Sep 01, 2021
End date: Apr 30, 2023
Enrollment: 524 participants

Primary outcome

The assessment of effectiveness of PAPILOCARE® in the regression of cervix cytological abnormalities caused by HPV.

Summary

The present study is a multicenter, open, non-interventional, prospective observational clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE mark) in the regression of cervix cytological abnormalities caused by HPV.

ICD-10 classifications

Papillomavirus as the cause of diseases classified to other chaptersPapovavirus infection, unspecified sitePapilloedema, unspecifiedViral infection, unspecifiedParvovirus as the cause of diseases classified to other chapters

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06399341
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT06399341 through Pure Global AI's free database. This phase not specified trial is sponsored by Elpen Pharmaceutical Co. Inc. and is currently Completed. The study focuses on Papillomavirus Infections. Target enrollment is 524 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.